Ketone inhibitors of lysine gingipain
The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis . Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
1. A compound according to Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is —CH 2 —;
R 1a , R 1b , R 2a , R 2b , and R 4 are hydrogen;
R 3 is selected from the group consisting of C 3-8 cycloalkyl, C 3-8 alkyl,
3- to 12-membered heterocyclyl, C 6-10 aryl, and 5- to 12-membered heteroaryl, wherein R 3 is optionally substituted with one or more R 3a substituents;
each R 3a is independently selected from the group consisting of halogen, —N 3 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, —N(R c ) 2 , —N + (R b ) 3 , and —NR c C(O)R b ;
each R b is independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 deuteroalkyl;
each R c is independently selected from the group consisting of hydrogen and C 1-8 alkyl;
R 5 is —CH 2 R 5a ; and
R 5a is —O-phenyl, wherein phenyl is substituted with 1-5 halogens;
provided that R 5 is other than 2,3,5, 6-tetrafluorophenoxymethyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having a structure according to Formula Ia:
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is C 3-8 cycloalkyl.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5a is selected from the group consisting of 2,3,6-trifluorophenoxy; 2,3,5-trifluorophenoxy; 2,3,4-trifluorophenoxy; 3,4,5-trifluorophenoxy; 2,3-difluorophenoxy; 2,4-difluorophenoxy; 2,5-difluorophenoxy; 2,6-difluorophenoxy; 3,4-difluorophenoxy; 3,5-difluorophenoxy; 2-fluorophenoxy; 3-fluorophenoxy; and 4-fluorophenoxy.
5. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein R 5a is selected from the group consisting of 2,3,6-trifluorophenoxy; 2,3,5-trifluorophenoxy; 2,3,4-trifluorophenoxy; 3,4,5-trifluorophenoxy; 2,3-difluorophenoxy; 2,4-difluorophenoxy; 2,5-difluorophenoxy; 2,6-difluorophenoxy; 3,4-difluorophenoxy; 3,5-difluorophenoxy; 2-fluorophenoxy; 3-fluorophenoxy; and 4-fluorophenoxy.
6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 5a is selected from the group consisting of 2,3,6-trifluorophenoxy; 2,3,5-trifluorophenoxy; 2,3,4-trifluorophenoxy; and 3,4,5-trifluorophenoxy.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:
9. The compound of claim 1 , which is
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 , which is
or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.